Literature DB >> 35907018

Macrophage migration inhibitory factor (MIF) and IgA anti CD74 antibodies in Indian patients with enthesitis-related arthritis category of Juvenile idiopathic arthritis.

Anu Balakrishnan1, Sanjukta Majumder1, Shivika Guleria1, Able Lawrence1, Amita Aggarwal2.   

Abstract

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine and has been implicated in pathogenesis of ankylosing spondylitis (AS). CD 74 is the receptor for MIF and IgA antiCD74 autoantibodies have been described from different parts of the world in patients with AS. As enthesitis-related arthritis (ERA) is a form of juvenile spondyloarthropathy, we studied the serum and synovial fluid levels of MIF in ERA and looked for the IgA antiCD74 antibodies in patients with ERA in our population. Patients with JIA (ILAR classification) were studied. Serum MIF levels were measured by ELISA in 101 patients of ERA (synovial fluid also where available) and compared to 28 patients of other categories of JIA, 25 patients each of ankylosing spondylitis and rheumatoid arthritis, and 38 healthy controls. In addition, association of MIF with disease activity was assessed. Ig A antiCD74 antibodies were measured in sera of ERA, AS and healthy controls. Median serum MIF levels were higher in ERA [2.50 (1.20-4.85) ng/ml] than in healthy controls [0.28 (0.16-0.48); p < 0.0001] and patients with RA [1.13 (0.44-2.45); p < 0.01] MIF levels in ERA were comparable to other categories of JIA [2.63 (1.70-4.05)] and patients with AS [3.62 (0.52-6.51)]. Synovial fluid MIF levels were higher than serum levels (p < 0.01). Serum MIF level had an association with the JSpADA score (r = 0.29, p < 0.01). Serum MIF levels had no association with presence of inflammatory markers, enthesitis, inflammatory back pain or sacroiliitis. IgA AntiCD74 antibody was positive only in 3/88 (3.41%) of ERA patients and was not detected in any patients of AS or healthy controls. Patients with ERA have high MIF levels that show modest correlation with disease activity. Higher synovial fluid MIF levels suggest that it may play a role in synovitis seen in ERA. IgA antiCD74 antibodies are rarely seen in ERA.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Disease activity; Enthesitis-related arthritis; Juvenile idiopathic arthritis; Macrophage migration inhibition factor

Year:  2022        PMID: 35907018     DOI: 10.1007/s00296-022-05173-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  14 in total

1.  International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

Authors:  Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

Review 2.  Anti-CD74 antibodies in spondyloarthritis: A systematic review and meta-analysis.

Authors:  Shanshan Xu; Xiaoyi Zhang; Yuting Chen; Yubo Ma; Jixiang Deng; Xing Gao; Shiyang Guan; Faming Pan
Journal:  Semin Arthritis Rheum       Date:  2020-12-10       Impact factor: 5.532

Review 3.  The immunobiology of MIF: function, genetics and prospects for precision medicine.

Authors:  Insoo Kang; Richard Bucala
Journal:  Nat Rev Rheumatol       Date:  2019-06-13       Impact factor: 20.543

4.  Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis.

Authors:  Vidya Ranganathan; Francesco Ciccia; Fanxing Zeng; Ismail Sari; Guiliana Guggino; Janogini Muralitharan; Eric Gracey; Nigil Haroon
Journal:  Arthritis Rheumatol       Date:  2017-08-13       Impact factor: 10.995

5.  CD74 is a novel transcription regulator.

Authors:  Naama Gil-Yarom; Lihi Radomir; Lital Sever; Matthias P Kramer; Hadas Lewinsky; Chamutal Bornstein; Ronnie Blecher-Gonen; Zohar Barnett-Itzhaki; Vita Mirkin; Gilgi Friedlander; Lev Shvidel; Yair Herishanu; Elias J Lolis; Shirly Becker-Herman; Ido Amit; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-28       Impact factor: 11.205

6.  Profile of Indian patients with juvenile onset chronic inflammatory joint disease using the ILAR classification criteria for JIA: a community-based cohort study.

Authors:  Vinaya Kunjir; Anuradha Venugopalan; Arvind Chopra
Journal:  J Rheumatol       Date:  2010-06-01       Impact factor: 4.666

Review 7.  Prevalence and incidence of juvenile idiopathic arthritis: a systematic review.

Authors:  Sigrid Thierry; Bruno Fautrel; Irène Lemelle; Francis Guillemin
Journal:  Joint Bone Spine       Date:  2013-11-06       Impact factor: 4.929

Review 8.  Enthesitis-related arthritis.

Authors:  Amita Aggarwal; Durga Prasanna Misra
Journal:  Clin Rheumatol       Date:  2015-08-02       Impact factor: 2.980

9.  Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies.

Authors:  Yuan Liu; Xining Liao; Guixiu Shi
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

Review 10.  Macrophage migration inhibitory factor: a regulator of innate immunity.

Authors:  Thierry Calandra; Thierry Roger
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.